Search
Bithionol
go.drugbank.com/drugs/DB04813ApprovedWithdrawnBithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).
Micronomicin
go.drugbank.com/drugs/DB13274ApprovedMicronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Colestilan chloride
go.drugbank.com/drugs/DB11634ApprovedWithdrawnColestilan is an ingredient in the EMA-withdrawn product BindRen.
Nomegestrol
go.drugbank.com/drugs/DB11636ApprovedNomegestrol is an ingredient in the EMA-authorised product Zoely.
GnRH pharmaccine
go.drugbank.com/drugs/DB05815ExperimentalThe pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation … The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle".
Vidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the
Synonyms: 9-β-D-arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-adenineVemtoberant
go.drugbank.com/drugs/DB21607InvestigationalVemtoberant has a monoisotopic molecular weight of 619.2 Da. … Vemtoberant is under investigation in clinical trial NCT05139615 (A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With
Delocamten
go.drugbank.com/drugs/DB21711InvestigationalDelocamten has a monoisotopic molecular weight of 377.16 Da. … Delocamten is under investigation in clinical trial NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection
Lonidamine
go.drugbank.com/drugs/DB06266InvestigationalIn such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. … Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalIn this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar.